Subgroup analysis of OS by liver metastases status at the time of 1L therapy showed a trend towards shorter OS for PD-L1–positive versus PD-L1–negative patients (median OS for absent: 31.6 versus 40.2 months; unstratified HR 1.24; 95% CI 1.02–1.50, present: 9.0 versus 25.3; unstratified HR 1.27; 95% CI 0.72–2.23; Fig. 3 , Supplementary Fig.
← all excerpts
Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma.
1
—
—